A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Iclepertin (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms CONNEX-3
- Sponsors Boehringer Ingelheim
- 06 May 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2024 Planned End Date changed from 31 Jan 2025 to 22 Nov 2024.
- 02 Apr 2024 Planned primary completion date changed from 3 Jan 2025 to 26 Oct 2024.